Cardiologist Eric Topol, director of Scripps Translational Science Institute in La Jolla, is a leading advocate of using a rapidly expanding array of genetic tests to screen patients for drug complications. Topol says that most physicians don’t take advantage of this new medical advance. He explored the potential consequences for patients in a commentary published Wednesday in the journal Science Translational Medicine. He wrote this article explaining his views for the Union-Tribune.
